Spyre Therapeutics, Inc. SYRE Common stock, shares issued (in shares)
Common stock, shares issued (in shares) at other companies
Other financials
Where this comes from
Reported directly by Spyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesIssued.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s common stock, shares issued (in shares).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s common stock, shares issued (in shares)?
- Spyre Therapeutics, Inc. (SYRE) reported common stock, shares issued (in shares) of $78.84M in Q1 2026.
- How has Spyre Therapeutics, Inc.'s common stock, shares issued (in shares) changed year-over-year?
- Spyre Therapeutics, Inc.'s common stock, shares issued (in shares) increased by 30.8% year-over-year, from $60.28M to $78.84M.
- What is the long-term trend for Spyre Therapeutics, Inc.'s common stock, shares issued (in shares)?
- Over 3 years (2022 to 2025), Spyre Therapeutics, Inc.'s common stock, shares issued (in shares) has grown at a 210.4% compound annual growth rate (CAGR), from $2.61M to $78.19M.